BioNTech SE (BNTX) — the peer cohort
As of 2026-11-16 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.
BioNTech SE ranks 16 of 16 in its cohort on the Closelooknet composite (35/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.
| Name | Composite | Momentum | Quality | Valuation | Signal | Off 52w high |
|---|---|---|---|---|---|---|
| BNTX BioNTech SE | 35 | 41 | 22 | 54 | bear | 31% |
| ASML.AS ASML Holding N.V. | 66 | 45 | 87 | 33 | bear | 23.1% |
| TEMN.SW Temenos Group AG | 64 | 72 | 90 | 42 | bull | 7.9% |
| SAN.PA Sanofi SA | 63 | 74 | 69 | 62 | watch | 1% |
| WKL.AS Wolters Kluwer N.V. | 63 | 92 | 83 | 64 | bull | 21.1% |
| CEVI.ST CellaVision AB | 61 | 96 | 72 | 27 | watch | 1.2% |
| REL.L Relx PLC | 61 | 84 | 84 | 53 | bull | 13.3% |
| SECT-B.ST Sectra AB (publ) | 60 | 83 | 67 | 10 | bull | 7% |
| DSY.PA Dassault Systemes SE | 58 | 88 | 74 | 38 | bull | 14.4% |
| HEXA-B.ST Hexagon AB (publ) | 57 | 82 | 66 | 42 | neutral | 10.3% |
| OXIG.L Oxford Instruments PLC | 57 | 38 | 59 | 50 | bear | 23.1% |
| ATCO-A.ST Atlas Copco AB Series A | 55 | 64 | 68 | 30 | watch | 10.2% |
| LR.PA Legrand SA | 55 | 48 | 64 | 42 | watch | 18.3% |
| HALO Halozyme Therapeutics Inc | 72 | 68 | 94 | 49 | info | 28% |
| ARGX.BR Argen-X | 64 | 79 | 75 | 25 | ok | 5.1% |
| UCB.BR UCB SA | 64 | 75 | 70 | 42 | info | 2% |
Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.
FAQ · from the current data · as of 2026-11-16
Quick answers
Who are BioNTech SE's peers in the Closelooknet universe?
The cohort is drawn from shared Closelooknet index membership first, then sector: ASML Holding N.V. (ASML.AS), Temenos Group AG (TEMN.SW), Sanofi SA (SAN.PA), Wolters Kluwer N.V. (WKL.AS), CellaVision AB (CEVI.ST), Relx PLC (REL.L), Sectra AB (publ) (SECT-B.ST), Dassault Systemes SE (DSY.PA) and others, as of 2026-11-16.
How does BNTX score against its peers?
BioNTech SE's composite reads 35/100, ranking 16 of 16 in its cohort as of 2026-11-16; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.
Related in the Closelooknet universe
same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ASML.AS ASML Holding N.V.
- TEMN.SW Temenos Group AG
- SAN.PA Sanofi SA
- WKL.AS Wolters Kluwer N.V.
- CEVI.ST CellaVision AB
- REL.L Relx PLC
- SECT-B.ST Sectra AB (publ)
- DSY.PA Dassault Systemes SE
- HEXA-B.ST Hexagon AB (publ)
- OXIG.L Oxford Instruments PLC
- ATCO-A.ST Atlas Copco AB Series A
- LR.PA Legrand SA
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- PTGX Protagonist Therapeutics Incindustry
- BION.SW BB Biotech AGindustry
- REPL Replimune Group Incindustry
- VCEL Vericel Corp Ordindustry